Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease

Rongxiu Huo,1,&ast; Qianyu Guo,1,&ast; Junping Hu,2 Na Li,1 Rui Gao,1 Liangyu Mi,1 Zhaoliang Zhang,1 Hechao Liu,1 Zhiying Guo,1 Hanxi Zhao,3 Liyun Zhang,1 Ke Xu1 1Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences; Tongji Shanxi Hospital,...

Full description

Bibliographic Details
Published in:	Drug Design, Development and Therapy
Main Authors:	Huo R, Guo Q, Hu J, Li N, Gao R, Mi L, Zhang Z, Liu H, Guo Z, Zhao H, Zhang L, Xu K
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-04-01
Subjects:	interstitial lung disease janus kinase signal transducers and activators of transcription jak inhibitor animal model.
Online Access:	https://www.dovepress.com/therapeutic-potential-of-janus-kinase-inhibitors-for-the-management-of-peer-reviewed-fulltext-article-DDDT

Similar Items

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022-07-01)

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
by: Huo R, et al.
Published: (2023-04-01)

The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights
by: Eric Toussirot
Published: (2022-02-01)

Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review
by: Nem Kumar Jain, et al.
Published: (2023-03-01)

Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
by: Satoshi Kubo, et al.
Published: (2018-06-01)

Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening
by: Angelika Pölläniemi, et al.
Published: (2023-06-01)

Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies
by: Toshiaki Kogame, et al.
Published: (2023-07-01)

Janus-kinase Inhibitors in Pathogenesis and Management of Chronic Urticaria: A Review of the Literature
by: Sepideh Darougar, et al.
Published: (2023-04-01)

Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A Review
by: Olimpia Wiciun, et al.
Published: (2025-05-01)

Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis
by: Ronan Talty, BS, et al.
Published: (2021-10-01)

Janus kinases: dermatological perspective, a review
by: Hanan R Nada, et al.
Published: (2020-01-01)

Janus kinase inhibitors in autoimmune bullous diseases
by: Dawei Huang, et al.
Published: (2023-07-01)

Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
by: Izabella Ryguła, et al.
Published: (2023-12-01)

Janus kinase inhibitors: between prescription authorization and reimbursability
by: F.R. Spinelli, et al.
Published: (2023-12-01)

Role of Janus-Kinases in Major Depressive Disorder
by: Anne Gulbins, et al.
Published: (2016-08-01)

Janus Kinase inhibitors in dermatology: a review
by: Bárbara Vieira-Granja, et al.
Published: (2023-01-01)

The Role of JAK/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms
by: Jia Liu, et al.
Published: (2023-01-01)

The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
by: Mei-qi Mao, et al.
Published: (2023-06-01)

The Janus Kinase Inhibitor Ruxolitinib Prevents Terminal Shock in a Mouse Model of Arenavirus Hemorrhagic Fever
by: Mehmet Sahin, et al.
Published: (2021-03-01)

Phytochemicals Targeting JAK–STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models
by: Sun Young Moon, et al.
Published: (2021-05-01)

Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes
by: Nina Yao, et al.
Published: (2021-10-01)

Itch and Janus Kinase Inhibitors
by: Yujin Han, et al.
Published: (2023-02-01)

Frequent <i>Klebsiella pneumoniae</i> Urinary Tract Infections in a Patient Treated with Ruxolitinib
by: Ramy M. Hanna, et al.
Published: (2019-09-01)

Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis
by: Peter J. Richardson, et al.
Published: (2023-10-01)

Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial
by: Xiaoling Liao, et al.
Published: (2023-10-01)

Tofacitinib Inhibits STAT Phosphorylation and Matrix Metalloproteinase-3, -9 and -13 Production by C28/I2 Human Juvenile Chondrocytes
by: Thorpe JR, et al.
Published: (2022-10-01)

Natural products for the treatment of ulcerative colitis: focus on the JAK/STAT pathway
by: Dan Long, et al.
Published: (2025-02-01)

The Upadacitinib - New Janus Kinase Inhibitor - Literature Review
by: Michalina Grzelka, et al.
Published: (2024-08-01)

Comparison of T cell response to vaccination in rheumatic patients treated with Janus kinase inhibitors and TNF inhibitors
by: Sebastian Hüper, et al.
Published: (2025-07-01)

Mechanism of Action of Exercise in Regulating Spontaneous Hypertension through the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Signaling Pathway
by: Yu Li, et al.
Published: (2025-04-01)

Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study
by: Atsuko Tsujii, et al.
Published: (2024-01-01)

MicroRNA-122 protects against interferon-α-induced hepatic inflammatory response via the Janus kinase–signal transducer and activator of transcription pathway
by: Fanwei Liu, et al.
Published: (2025-01-01)

Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues
by: Milo Gatti, et al.
Published: (2021-07-01)

Janus kinase inhibitors for alopecia areata: a review of clinical data
by: Yutong Sun, et al.
Published: (2025-05-01)

Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysisCapsule Summary
by: Daniel Isufi, BSc(Med), et al.
Published: (2025-02-01)

Janus kinase inhibition in the treatment and prevention of graft-versus-host disease
by: Elisa De Togni, et al.
Published: (2024-02-01)

Modulation of IL-6 receptor/STAT3 downstream signaling in rheumatoid arthritis patients
by: Fabio Cacciapaglia, et al.
Published: (2025-03-01)

Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia
by: Giulia Veltri, et al.
Published: (2022-07-01)

Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
by: Jiao Wang, et al.
Published: (2025-02-01)

Resveratrol suppresses neuroinflammation to alleviate mechanical allodynia by inhibiting Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway in a rat model of spinal cord injury
by: Jie Han, et al.
Published: (2023-02-01)